Tuesday, February 13, 2018

MassRoots Announces Plan to Scale its Market Share in Multi-Billion Dollar California Market

Source:  MassRoots, Inc.

Company discusses strategy on eve of first recreational cannabis sales 

MassRoots, Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the leading technology platforms for the regulated cannabis industry, today announced a comprehensive action plan to aggressively scale its market share of cannabis consumers and businesses in the California market. On January 3, 2018, the first recreational cannabis sales are expected to begin in California, which ArcView Market Research projects will grow to $6.5 billion by 2020.

Powered by more than one million registered users, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., effectiveness for treating ailments such as back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary. Businesses are able to leverage MassRoots by strategically advertising to consumers based on their preferences and tendencies.

MassRoots has launched a comprehensive social media campaign leveraging its 450,000 followers on Instagram, 500,000 followers on Facebook, and more than 100,000 followers on Snapchat, in addition to its network of more than 75 cannabis-centric social media influencers with combined followings of more than 5,000,000 people. The campaign is focused on driving and rewarding referrals of users and paying businesses to the MassRoots platform.

"We believe California offers the opportunity of a lifetime for MassRoots and its shareholders," stated MassRoots Chief Executive Officer Mr. Isaac Dietrich.  "There are thousands of businesses are in the process of revamping their operations to be in compliance with newly-implemented state regulations. Our goal is to have as many of these business processes utilizing the MassRoots platform as possible and establish our Company as a dominant player in the California cannabis market."

About MassRootsMassRoots, Inc. is one of the leading technology platforms for the regulated cannabis industry. Powered by more than one million registered users, the Company's mobile apps empower consumers to make educated cannabis purchasing decisions through community-driven reviews. Its compliance and point-of-sale system, MassRoots Retail, enables cannabis-related businesses to streamline their retail operations and manage compliance reporting to state regulators. With a significant market share of medical cannabis patients in certain markets and more than 25,000 shareholders, the Company believes it is uniquely positioned to best serve the needs of the cannabis industry. For more information, please visit MassRoots.com/Investors and review MassRoots' filings with the U.S. Securities and Exchange Commission.

MassRoots Retires Convertible Debt

Source:  MassRoots, Inc.

Company continues to strengthen its balance sheet as it expands into blockchain technology for the cannabis industry

MassRoots, Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the leading technology platforms for the regulated cannabis industry, today announced all notes issued pursuant to the Company's August 2017 debt offering have been retired and the Company has no further obligations under the notes of that offering. More information is available on the Company's Current Report on Form 8-K filed on January 17, 2018.

"We're excited to have this convertible debt fully retired as we continue to strengthen MassRoots' balance sheet and drive shareholder value," stated MassRoots Chief Executive Officer Mr. Isaac Dietrich. "With California's recreational cannabis market recently coming online and our expansion into blockchain technology, we believe MassRoots is well positioned to deliver growth in 2018."
Powered by more than one million registered users, MassRoots enables consumers to rate products and strains based on their efficacy (i.e., effectiveness for treating ailments such back-pain or epilepsy) and then presents this information in easy-to-use formats for consumers to make educated purchasing decisions at their local dispensary. Businesses are able to leverage MassRoots by strategically advertising to consumers based on their preferences and tendencies. More information on MassRoots' blockchain expansion is available at www.MassRootsBlockchain.com.

About MassRoots
MassRoots, Inc. is one of the leading technology platforms for the regulated cannabis industry. Powered by more than one million registered users, the Company's mobile apps empower consumers to make educated cannabis purchasing decisions through community-driven reviews. Its compliance and point-of-sale system, MassRoots Retail, enables cannabis-related businesses to streamline their retail operations and manage compliance reporting to state regulators. With a significant market share of medical cannabis patients in certain markets and more than 25,000 shareholders, the Company believes it is uniquely positioned to best serve the needs of the cannabis industry. For more information, please visit MassRoots.com/Investors and review MassRoots's filings with the U.S. Securities and Exchange Commission.

MassRoots Forms Subsidiary for Blockchain-Based Solutions for the Cannabis Industry

 Source:  MassRoots, Inc.

MassRoots, Inc. ("MassRoots" or the "Company") (OTCQB:MSRT), one of the leading technology platforms for the regulated cannabis industry, today announced it has formed MassRoots Blockchain Technologies, Inc., a wholly-owned subsidiary of MassRoots, Inc. dedicated to developing blockchain-based solutions for the cannabis industry. More information is available at www.MassRootsBlockchain.com.

"We believe blockchain has the potential to enable the cannabis industry to operate more efficiently and with a greater degree of accountability and transparency," stated MassRoots Chief Executive Officer Isaac Dietrich. "MassRoots looks forward to being a pioneer in exploring blockchain-based solutions for the multi-billion dollar cannabis industry."

"The blockchain is an incorruptible digital ledger of economic transactions that can be programmed to record not just financial transactions but virtually everything of value," according to Dan and Alex Tapscott in the Blockchain Revolution (2016). The most well-known application to blockchain technology has been cryptocurrencies, which have grown to a market valued at more than $600 billion, according to CoinMarketCap.com. The broadening of this technology spans many other applications and creates various opportunities within the regulated cannabis market.

Seed-to-Sale TrackingDistributed ledger technology provides a greater degree of reliability and accuracy on the metadata associated with products -- times, dates, locations, quantities -- which have the potential to reduce friction in the cannabis market-place, save businesses valuable resources, and provide greater transparency to government regulators. According to Bloomberg, IBM is also exploring how blockchain can improve seed-to-sale traceability in the cannabis market. MassRoots Blockchain is exploring how this new technology can improve its point-of-sale system, MassRoots Retail, formerly known as Odava.

Smart ContractsBlockchain enables the development of contracts that automatically execute when certain parameters are met -- for example, a dispensary can automatically order more supply of a particular strain when its inventories reach a certain threshold. The smart contract has the potential to add substantial efficiency to the supply chain and resource planning processes within the cannabis industry. MassRoots Blockchain is exploring how to integrate this technology with its platform.

Eliminating Intermediaries
In the sharing economy as it exists today, buyers and sellers have to go through intermediaries to conduct a transaction (such as AirBnB for short-term rentals and Uber for ride-sharing). The blockchain enables peer-to-peer transactions without third parties, meaning that personal and business reputation can be verified and thus more reliable. MassRoots Blockchain is exploring how this can be applied to producers of cannabis and the dispensaries that purchase from them.

Corporate GovernanceBlockchain has the potential to make the validation and results of elections fully-transparent and immediately accessible online. MassRoots Blockchain is exploring how distributed-ledger technology can be applied to proxy voting and giving MassRoots' shareholders a greater degree of transparency and communication.

Identity ManagementSocial networks such as MassRoots collect a significant amount of metadata on its users. Blockchain has the potential to streamline its collection and organization, while eliminating traditional security risks. This would enable advertisers to better target consumers, reduce the risk of security breaches, and enable the development of solutions that better serve the MassRoots community.

About MassRootsMassRoots, Inc. is one of the leading technology platforms for the regulated cannabis industry. Powered by more than one million registered users, the Company's mobile apps empower consumers to make educated cannabis purchasing decisions through community-driven reviews. Its compliance and point-of-sale system, MassRoots Retail, enables cannabis-related businesses to streamline their retail operations and manage compliance reporting to state regulators. With a significant market share of medical cannabis patients in certain markets and more than 25,000 shareholders, the Company believes it is uniquely positioned to best serve the needs of the cannabis industry. For more information, please visit MassRoots.com/Investors and review MassRoots' filings with the U.S. Securities and Exchange Commission.

Wednesday, February 7, 2018

Actinium Pharmaceuticals Reminds Investors of Record Date for Rights Offering

Source:  Actinium Pharmaceuticals, Inc.


- Record date established as February 14, 2018 
- To be a shareholder of record, investors are advised to own Actinium stock by 4:00 PM ET, Monday, February 12, 2018 to account for T+2 settlement timing 
- Actinium’s executive management and directors have indicated their intent to subscribe to the rights offering



Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), today issued a reminder to shareholders that the Record Date of its proposed rights offering is February 14, 2018. To be a shareholder of record, ownership of Actinium stock must occur by market close of February 12, 2018 to account for settlement. 

Under the proposed rights offering, Actinium would distribute non-transferable subscription rights to purchase 35,714,285 units at a subscription price per unit of $0.70, to its stockholders and certain participating warrant holders on the record date.  The subscription rights will be exercisable for up to an aggregate of $25.0 million of units, subject to increase at the discretion of the Company, with aggregate participation to be allocated among holders on a pro rata basis if in excess of that threshold.

Each unit will consist of one share of common stock, 0.25 series A warrants and 0.75 series B warrants.  The series A warrants will have a term of 12 months from the date of issuance and will be exercisable at a price of $0.90.  The series B warrants will have a term of 30 months from the date of issuance and will have an exercise price of $1.10.  Holders who fully exercise their basic subscription rights will be entitled, if available, to subscribe for an additional amount of units that are not purchased by other holders, on a pro rata basis and subject to the $25.0 million aggregate offering threshold and other ownership limitations.  The subscription rights are non-transferrable and may only be exercised during the anticipated subscription period of Thursday, February 15, 2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.

Actinium’s executive management and directors have indicated their intent to subscribe to the rights offering.  Investors are advised to ensure they own Actinium’s stock as of 4:00 PM ET on Monday, February 12, 2018 to be considered a stockholder of record on Wednesday, February 14, 2018, to take into account T+2 settlement timing.

The expected calendar for the rights offering is as follows:
  • Monday, February 12, 2018: Buy-In Deadline - to be considered a stockholder of record on Wednesday, February 14, 2018, shares should be acquired by this date.
  • Wednesday, February 14, 2018: Record Date*
  • Thursday, February 15, 2018: Distribution Date; Subscription Period Begins
  • Friday, March 2, 2018: Subscription Period Ends 5:00 PM ET*
* Unless extended in Actinium’s sole discretion

Actinium intends to use the proceeds from the rights offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate Iomab-B, generate topline results and support the filing of a BLA application with the U.S. Food and Drug Administration (FDA) all of which are anticipated to be approximately $12 to 15 million.  Iomab-B is a first in class therapy being developed for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.  The SIERRA trial is randomized and controlled 150-patient trial that is currently active at 15 clinical trial sites in the United States.  Actinium’s CD33 program is currently comprised of an ongoing Phase 2 clinical trial for Actimab-A and Phase 1 trial for Actimab-M which are expected to generate top line results in 2018 as well as a planned Phase 2 trial for Actimab-MDS.  The Company intends to partner the CD33 program and believes that data from these trials as well as the Actimab-MDS trial will support this strategy and establish its program as the industry leader.  Consequently, the Company may elect to use any additional proceeds above $15 million to fund proof-of-concept of its planned Phase 2 Actimab-MDS trial from the CD33 Program, if appropriate, as it believes this can further support its partnering strategy for the CD33 program.  Actinium will also use the proceeds to support its AWE Technology Platform, research and development and general working capital needs. 

Actinium has engaged Maxim Group LLC as dealer-manager for the Rights Offering.  Questions about the rights offering or requests for a prospectus may be directed to Broadridge Corporate Issuer Solutions, Inc., Actinium’s information agent for the rights offering, by calling (855) 793-5068 (toll-free); or to Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A registration statement on Form S-3 relating to these securities has been filed by the Company with the SEC.  The rights offering will only be made by means of a prospectus.  A preliminary prospectus relating to and describing the proposed terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s web site.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.  Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival.  Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.  Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac225) that emits alpha particles.  We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform.  Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131.  We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.  A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders.  Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results.  Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug.  We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225.  Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy.  Actimab-A also has Orphan Drug designation in the US and EU.  Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma.  Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation.  Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com

Actinium Pharmaceuticals Announces Trial to Study Actimab-A in Combination with CLAG-M for Relapsed or Refractory AML Patients





Source:  Actinium Pharmaceuticals, Inc.


- Actimab-A plus CLAG-M further expands Actinium’s CD33 program and addressable patient population of Actimab-A 
- Combination aligns with Actinium’s focus on improving bone marrow transplant access and outcomes through improved myeloablation
- Conference call to be held on Tuesday, February 13, 2018 at 4:30 PM ET



Actinium Pharmaceuticals, Inc.  (NYSE American:ATNM) ("Actinium" or "the Company"), announced today that the Company is initiating a new clinical trial that will study Actimab-A in combination with CLAG-M for patients with relapsed or refractory acute myeloid leukemia (AML).  CLAG-M is a salvage chemotherapy regimen that consists of cladribine, cytarabine, and filgrastim with mitoxantrone for patients with relapsed or refractory AML.  The combination trial will be a Phase 1, dose-escalation study that will be conducted at the Medical College of Wisconsin by principal investigator Dr. Ehab Atallah.

Dr. Mark Berger, Actinium’s Chief Medical Officer said, “Relapsed and refractory AML patients unfortunately have limited treatment options that have little clinical benefit for patients.  Actimab-A is ideally suited to be studied in combination with other therapeutic modalities like CLAG-M given its potency and minimal extramedullary toxicities.  We are optimistic that this novel combination will demonstrate Actimab-A’ s key strengths through higher response rates, a greater number of patients successfully receiving a bone marrow transplant and ultimately, survival.  Further, it will demonstrate the value of using Actimab-A in combinations as we believe that combination therapies will be the next wave in the treatment of patients with AML just as combinations of regimen’s approved in multiple myeloma over the past three or four years have become for patients with that disease.”

Actinium will host a conference call on Tuesday, February 13, 2018 at 4:30 PM ET that will be led by Dr. Mark Berger, Actinium’s Chief Medical Officer and Dr. Atallah.

Webcast Registration: https://onecast.thinkpragmatic.com/ses/d4PAnC1sn4SzZZdJjklZQA~~
U.S. Participant Dial-in: (646) 402-9440
U.S./Canada Toll Free Dial-in: (855) 698-6739
Conference ID: 2540

Sandesh Seth, Actinium’s Chairman and CEO said, “This latest clinical initiative is especially exciting as it further demonstrates that we are building the industry leading CD33 Program.  We the only company with multi-disease, multi-indication clinical trials with our ongoing Actimab-A, Actimab-M and planned Actimab-MDS studies and this latest initiative has the potential of extending the addressable patient population for Actimab-A.  This is a viable approach for Actimab-A as we begin to strategize and implement the next phase of Actimab-A’s development.   In doing so, we expect to maximize the value of our CD33 program and increase its synergies for potential partners and collaborators.  Further, this initiative is aligned with Actinium’s core strategy of improving access and outcomes to transplants and one we are excited to embark on.”

Actimab-A is Actinium’s lead drug candidate from its CD33 program and is an Antibody Radio-Conjugate (ARC) that is comprised of the CD33 targeting antibody lintuzumab and actinium-225, an alpha-emitting radioisotope.  Actimab-A is currently being studied in Phase 2 clinical trial in patients that are newly diagnosed with AML who are over the age of 60 that are ineligible for intense chemotherapy, also known as unfit patients.  The Company expects to complete patient enrollment of the Phase 2 trial in the first half of 2018 and report top line data results in the second half of 2018.  The Company is also developing Actimab-M and Actimab-MDS, which are also CD33 actinium-225 ARCs.  Actimab-M is being studied in a Phase 1 investigator-initiated trial for patients with refractory multiple myeloma. The Phase 1 Actimab-M trial is expected to complete enrollment and report top like data in the second half of 2018.  Actimab-MDS is expected to begin a Phase 2 clinical trial in the second half of 2018 following a pre-IND meeting with the FDA in the first half of 2018.  Actimab-MDS is intended to bridge patients with high-risk myelodysplastic syndrome (MDS) that have a p53 genetic mutation to a bone marrow transplant via targeted myeloablation. 

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.  Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival.  Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.  Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac225) that emits alpha particles.  We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform.  Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131.  We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.  A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders.  Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results.  Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug.  We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225.  Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy.  Actimab-A also has Orphan Drug designation in the US and EU.  Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma.  Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation.  Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com






Actinium Pharmaceuticals Announces Rights Offering





Source:  Actinium Pharmaceuticals, Inc.


Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has filed a preliminary prospectus supplement as a part of a registration statement on Form S-3 with the Securities and Exchange Commission (SEC) for a rights offering to stockholders and certain participating warrant holders of record on Wednesday, February 14, 2018.

Under the proposed rights offering, Actinium would distribute non-transferable subscription rights to purchase 35,714,285 units at a subscription price per unit of $0.70, to its stockholders and certain participating warrant holders on the record date.  The subscription rights will be exercisable for up to an aggregate of $25.0 million of units, subject to increase at the discretion of the Company, with aggregate participation to be allocated among holders on a pro rata basis if in excess of that threshold.

Each unit will consist of one share of common stock, 0.25 series A warrants and 0.75 series B warrants.  The series A warrants will have a term of 12 months from the date of issuance and will be exercisable at a price of $0.90.  The series B warrants will have a term of 30 months from the date of issuance and will have an exercise price of $1.10.  Holders who fully exercise their basic subscription rights will be entitled, if available, to subscribe for an additional amount of units that are not purchased by other holders, on a pro rata basis and subject to the $25.0 million aggregate offering threshold and other ownership limitations.  The subscription rights are non-transferrable and may only be exercised during the anticipated subscription period of Thursday, February 15, 2018 through 5:00 PM ET on Friday, March 2, 2018, unless extended.

Investors are advised to ensure they own Actinium’s stock as of 4:00 PM ET on Monday, February 12, 2018 to be considered a stockholder of record on Wednesday, February 14, 2018, to take into account T+2 settlement timing.

The expected calendar for the rights offering is as follows:
  • Monday, February 12, 2018: Buy-In Deadline - to be considered a stockholder of record on Wednesday, February 14, 2018, shares should be acquired by this date.
  • Wednesday, February 14, 2018: Record Date*
  • Thursday, February 15, 2018: Distribution Date; Subscription Period Begins
  • Friday, March 2, 2018: Subscription Period Ends 5:00 PM ET *
* Unless extended in Actinium’s sole discretion

Actinium intends to use the proceeds from the rights offering to complete its ongoing pivotal, Phase 3 SIERRA trial for its lead product candidate Iomab-B, generate topline results and support the filing of a BLA application with the U.S. Food and Drug Administration (FDA) all of which are anticipated to be approximately $12 to $15 million.  Iomab-B is a first in class therapy being developed for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.  The SIERRA trial is randomized and controlled 150-patient trial that is currently active at 15 clinical trial sites in the United States.  Actinium’s CD33 program is currently comprised of an ongoing Phase 2 clinical trial for Actimab-A and Phase 1 trial for Actimab-M which are expected to generate top line results in 2018 as well as a planned Phase 2 trial for Actimab-MDS.  The Company intends to partner the CD33 program and believes that data from these trials as well as the Actimab-MDS trial will support this strategy and establish its program as the industry leader.  Consequently, the Company may elect to use any additional proceeds above $15 million to fund proof-of-concept of its planned Phase 2 Actimab-MDS trial from the CD33 Program, if appropriate, as it believes this can further support its partnering strategy for the CD33 program.  Actinium will also use the proceeds to support its AWE Technology Platform, research and development and general working capital needs. 

Actinium has engaged Maxim Group LLC as dealer-manager for the Rights Offering.  Questions about the rights offering or requests for a prospectus may be directed to Broadridge Corporate Issuer Solutions, Inc., Actinium’s information agent for the rights offering, by calling (855) 793-5068 (toll-free); or to Maxim Group LLC, 405 Lexington Avenue, New York, NY 10174, Attention Syndicate Department, email: syndicate@maximgrp.com or telephone (212) 895-3745.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

A registration statement on Form S-3 relating to these securities has been filed by the Company with the SEC.  The rights offering will only be made by means of a prospectus.  A preliminary prospectus relating to and describing the proposed terms of the rights offering has been filed with the SEC as a part of the registration statement and is available on the SEC’s web site.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells.  Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival.  Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes.  Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac-225) which emits alpha particles.  We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform.  Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131.  We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.  A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders.  Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results.  Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug.  We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter Ac-225.  Our most CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy.  Actimab-A also has Orphan Drug designation in the US and EU.  Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma.  Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation.  Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac-225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com

Actinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster Product

Source:  Actinium Pharmaceuticals, Inc.

Poster to present additional data showcasing ability of Actinium’s AWE Technology to yield a potential biobetter of daratumumab, a blockbuster CD38 targeted therapy for multiple myeloma


Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that its abstract has been accepted for a poster presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois.  The abstract showcases the potential of Actinium’s AWE Technology Platform, specifically, the ability of actinium-225 to enhance the in vivo efficacy of daratumumab, a CD38 targeting therapy that is marketed by Johnson & Johnson as Darzalex®.  

Per the abstract submission highlighted below, the Ac-225 labelled daratumumab at an equimolar concentration demonstrated superior antitumor activity to naked daratumumab in a highly predictive DAUDI model and provided a survival benefit.  Additional details will be available at the time of the Annual Meeting.  The Company had earlier presented initial in vitro data at ASH which studied the effect of Actinium-225 labeled daratumumab on DAUDI, 28BM and 28PE cell lines at the 48, 72 and 96 hour time points as well as U226, a cell line that does not express CD38.  The results showed that when daratumumab is labeled with Actinium-225, cell death was increased as much as ten-fold, approaching one-hundred percent cell death in certain cell lines and at certain time points, and in all three cell lines tested the Actinium-225 labeled daratumumab had higher cell death compared to naked daratumumab.  In addition, immunogenicity was preserved with most or all of daratumumab’s CD38 targeting ability maintained, high rates of radioisotope labeling of the antibody from 82-85% was demonstrated, as was high rates of stability from 73-87% at various temperatures forty-eight hours post labeling.

Details on the poster are as follows:

Title: Conjugation of daratumumab with 225actinium greatly increases its antitumor activity against multiple myeloma tumors
Abstract Number: 760
Session Category: Experimental and Molecular Therapeutics

Sandesh Seth, Actinium’s Chairman and Chief Executive Officer said, “We are excited to build upon the already exciting data from our AWE Program and are looking forward to presenting new data from our continued efforts.  The data we will present will exemplify Actinium’s expanding R&D capabilities and the potential of our AWE technology platform, which are now being spearheaded by our new Chief Scientific Officer, Dr. Dale Ludwig. This is the first AACR that Actinium has presented data at and we look forward to a growing and impactful presence as we are committed to continuing to leverage our AWE technology and extending our capabilities both on behalf of our internal efforts but also for partners”

About Our Actinium Warhead Enabling Technology Platform
The Actinium Warhead Enabling (AWE) Technology Platform enables a highly potent and selective form of targeted therapy that combines the powerful alpha-emitting radioisotope actinium-225 with targeting agents, which are designed to seek out cancer cells in the body that express particular markers. Actinium-225 emits significant alpha radiation making it a potent treatment modality against targeted cancer cells while limiting damage to healthy tissues as its radiation travels extremely short distances in the body. When labeled to targeting agents, actinium-225 can be delivered directly to cancer cells where the high linear energy transfer resulting from the emission of alpha particles results in irreparable DNA double stranded breaks and ultimately cancer cell death.  Despite this superior cell killing power, actinium-225 when delivered in a targeted manner is sparing of the surrounding environment in the body due to the short path length of its alpha-particle radiation and can result in a superior safety profile. Actinium Pharmaceuticals owns or has licensed the rights to several issued and pending patents that pertain to its AWE Technology Platform including technology to manufacture Actinium-225 in a cyclotron. In addition, the Company obtains actinium-225 from various sources such as the U.S. Department of Energy at Oak Ridge National Laboratories and has developed considerable know-how, expertise and validated processes related to production of Actinium Radio-Conjugates (ARC’s), management of the supply chain and dealing with various regulatory bodies. The AWE Technology Platform can be utilized to potentially improve the cell-killing power of targeting agents such as antibodies, peptides, Fab fragments, nanobodies etc. via labeling with Actinium-225. In addition to increased efficacy, these Actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation of biobetters or improved versions of the approved agent. The Company’s Actinium Warhead Enabling (AWE) Program can be accessed by biopharmaceutical companies that are interested in creating biobetters through the utilization of the AWE Platform Technology. To learn more about the AWE Technology Platform or the AWE Program please contact Keisha Thomas, Ph.D., Corporate Development at kthomas@actiniumpharma.com.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC’s or Actinium Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac-225) which emits alpha particles. We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform. Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter Ac-225. Our most CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac-225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com

Actinium Pharmaceuticals Issues Letter to Investors Providing Company Update and Outlook for 2018

Source:  Actinium Pharmaceuticals, Inc.

Strong finish to 2017 sets stage for series of value enhancing milestones in 2018

Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company") announced today that it has issued a letter to investors providing a company update and outlook for 2018.  The letter to investors is available on the Company’s investor relations page of its website https://ir.actiniumpharma.com/shareholder-letters.  In addition, an 8-K has been filed with the SEC. 

Sandesh Seth, Actinium’s Chairman and CEO said, “In December 2017, we announced several exciting developments that exemplify Actinium’s functionality, enhanced capabilities, and most importantly, a focus on execution.  We finished 2017 with strong momentum in our Iomab-B and Actimab-A clinical programs, added to our CD33 program and growing bone marrow transplant franchise with the announcement of Actimab-MDS and reinvigorated our research and development efforts with the launch of our AWE Program.  This momentum gives our team phenomenal energy for 2018 and we look forward to continued strong execution on the numerous clinical milestones that we expect can unlock significant value for investors.”

Year End 2017 Highlights:
  • Announced Actimab-MDS, a new clinical initiative focused on improving transplant outcomes as measured by 1-year overall survival for patients with high-risk myelodysplastic syndrome with a p53 genetic mutation.  We intend to begin a Phase 2 trial with Actimab-MDS that will be led by principal investigator Dr. Gail Roboz of Weill-Cornell and the MDS Clinical Research Consortium that is comprised of the Cleveland Clinic, Dana-Farber Cancer Institute, Johns Hopkins, MD Andersen Cancer Center, Moffitt Cancer Center.
  • Presented Phase 2 data at ASH from our Actimab-A clinical trial showing a 69% overall response rate in patients with AML who are older and unfit for induction chemotherapy.  Actimab-A produced these results as a single agent that is administered via two infusions on day 1 and day 8.

  • Launched the AWE Program that is focused on creating ARCs or antibody radio-conjugates or biobetters utilizing actinium-225 in partnership or collaboration with biopharmaceutical companies.

  • Presented preliminary preclinical data from our AWE Program at ASH where we showed an up to ten-fold increase in the cell killing ability of daratumumab, a blockbuster CD38 antibody therapy for patients with multiple myeloma that is marketed by Johnson & Johnson.

  • An abstract was published  in the ASH volume of blood® confirming the expression of CD33 in patients with multiple myeloma from a large U.S. patient database, providing further validation for our Actimab-M clinical trial in refractory multiple myeloma patients, which is the first CD33 targeted therapy for this patient population.
  • Announced that the independent data monitoring committee reviewed initial data from the first 20 patients in the pivotal Phase 3 SIERRA trial for Iomab-B and recommended that the trial continue as planned.
2018 Outlook:

Unlocking Significant Value in Myeloablation for Bone Marrow Transplant

With the announcement of Actimab-MDS, Actinium is now the only company with a multi-disease, multi-product pipeline focused on improving bone marrow transplant access and outcomes via improved myeloablation.  Bone marrow transplant is a potentially curative treatment option for patients with blood cancers and diseases such as leukemias, lymphomas and myelodysplastic syndromes.  A majority of bone marrow transplants are performed in fifty leading hospitals in the U.S., which is where Actinium will initially focus and build on its existing presence in leading centers that account for over 35 percent of transplant volume.  Actinium is committed to building a franchise serving the bone marrow transplant market and expects to achieve the following milestones in 2018 and beyond for Iomab-B as it strives to be the leader in the field:
Iomab-B:
  • Complete enrollment of the pivotal Phase 3 SIERRA trial for Iomab-B by the end of 2018
  • Have successful DMC safety analyses when 25%, 50% and 75% of patients have been enrolled and potential interim analyses when 70 and 110 patients have reached the primary endpoint
  • Report topline data results in the second half of 2019
  • Prepare for a BLA filing to obtain FDA approval
  • Scale up for commercial operations
Actimab-MDS:
  • Have a meeting with the FDA in the first half of 2018 to set a regulatory pathway
  • Initiate Phase 2 clinical trial in the second half of 2018
Building an Industry Leading CD33 Program with Multiple Shots on Goal

The Company is developing a potentially leading CD33 targeting program in the industry with clinical programs in three indications. Actinium is the only commercial sponsor to have a clinical trial in multiple myeloma that is focused on targeting CD33.  In addition, Actinium is the only commercial sponsor to utilize an alpha particle payload in these radiation sensitive cancers.  Actinium believes the following programs are best-in-class and/or first-in-class:
  • Actimab-A for unfit elderly AML patients in Phase 2
  • Actimab-M for refractory multiple myeloma in a proof of concept Phase 1 trial
  • Actimab-MDS for BMT conditioning in high-risk MDS patients with a planned Phase 2
Actinium expects numerous milestones from these programs in 2018 including:

Actimab-A:
  • Complete enrollment of the Phase 2 trial in the first half of 2018
  • Report top line data in the second half of 2018
 Actimab-M:
  • Complete enrollment of the Phase 1 trial in second half of 2018
  • Report top line data by the end of 2018
Actimab-MDS:
  • Have a meeting with the FDA in the first half of 2018 to set a regulatory pathway
  • Initiate Phase 2 clinical trial in the second half of 2 clinical trial
Leading Innovation Via the AWE Technology Platform

Actinium announced its Actinium Warhead Enabling or AWE Technology Platform to capitalize on the utilization of actinium-225 to enhance the cell killing power of targeting agents such as antibodies, peptides, Fab fragments and other modalities.  Using the AWE program, Actinium intends to create ARCs or antibody radio-conjugates and biobetters in collaboration or partnership with biopharmaceutical companies.  In January, Actinium announced that Dr. Dale Ludwig was appointed Chief Scientific Officer and would be tasked with managing the AWE Technology Platform. In 2018, Actinium expects to achieve the following with its AWE Program:
  • Present additional data from its work with labeling daratumumab with actinium-225
  • Label additional targeting agents with actinium-225
  • Secure a collaboration based on the AWE Technology Platform
The Company reiterates its intent to build upon the promise of both the CD45 and CD33 programs over the next three to five years by gaining approval and commercializing multiple product candidates based on these programs to enhance access to bone marrow transplant with improved outcomes via its improved myeloablation approach and to partner strategically to enhance the value of its programs and technology platforms.  

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac-225) which emits alpha particles. We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform. Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter Ac-225. Our most CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac-225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs


Source:  Actinium Pharmaceuticals, Inc.

- Dr. Ludwig brings over 20 years of leadership and management expertise from Eli Lilly and Company and Imclone Systems, Inc. in oncology antibody therapeutics discovery and 
development where he supported the development and launch of Erbitux®, CyramzaTM
Portrazza®, and LartruvoTM, and the clinical advancement of 10 additional therapeutic 
antibodie 

- Actinium’s recently announced Actinium Warhead Enabling Technology Platform is focused 
on the generation of antibody radio-conjugates and biobetters designed to expand Actinium’s 
pipeline and facilitate collaborations


Actinium Pharmaceuticals, Inc.  (NYSE American:ATNM) ("Actinium" or "the Company"), announced today that Dr. Dale L. Ludwig has been appointed Chief Scientific Officer. Dr. Ludwig joins Actinium from Eli Lilly and Company, and prior to that Imclone Systems Inc., serving most recently as Chief Scientific Officer/Vice President, Oncology Discovery Research – Biologics Technology. Dr. Ludwig will be responsible for leading the Company’s initiatives on its Actinium Warhead Enabling (AWE) Technology Platform and the AWE Program that is focused on the utilization of the payload actinium-225 (Ac225) in conjunction with targeting agents to create Antibody Radio-Conjugates or ARC’s and bio-betters with the goal of expanding Actinium’s clinical pipeline and facilitating collaborations. In addition, Dr. Ludwig will also lead preclinical program development and support clinical development programs via translational research efforts. 

“I am incredibly excited and honored to be joining Actinium Pharmaceuticals,” said Dr. Dale Ludwig. “Having worked successfully in the discovery and development of therapeutic antibodies for oncology most of my professional career, I recognized the potential therapeutic value of Actinium’s ARC or Antibody Radio-Conjugate approach utilizing an actinium-225 isotope payload. Actinium has assembled a team that is committed to the advancement of this potentially transformational technology with its Ac225 based clinical programs and to further develop the AWE Technology Platform. I am thrilled to be a part of the Actinium team and to contribute to building a pioneering company that creates value through the development of novel ARC based therapeutics that improve patient outcomes.”  

Dr. Ludwig was a member of the Oncology Research Senior Leadership Team at Eli Lilly and Company. Dr. Ludwig brings to Actinium proven leadership and research management expertise through his work at Eli Lilly and prior to that at Imclone Systems Inc. where he supported the development and successful launch of several biologic oncology drugs including Erbitux®, CyramzaTM, Portrazza®, and LartruvoTM as well as the clinical advancement of 10 additional therapeutic antibodies. Most recently, Dr. Ludwig served Chief Scientific Officer/Vice President of Oncology Discovery Research - Biologics Technology at Eli Lilly. In this role he was responsible for directing antibody discovery and development for oncology biologics and contributed to key strategic and project advancement efforts. In addition, Dr. Ludwig also brings significant alliance management experience having directed the empowered antibody drug discovery programs that included collaborations with Immunogen and Zymeworks. 

Sandesh Seth, Actinium’s Chairman and CEO said, “Dr. Ludwig has enjoyed a successful career at Eli Lilly and Imclone where he developed and built his expertise in biologic drug discovery and development as well as his leadership skills, making him the ideal addition to the Actinium team. I am incredibly excited to have Dale on board, particularly at this pivotal juncture in Actinium’s progression and am confident that under his leadership the Company will have significant accomplishments related to its research efforts and further development of the AWE Technology Platform. Clearly our industry leading CD33 Program is a testimony to the power of the AWE technology platform and the ability of ARC’s to be effective where antibody-arming approaches using toxins have less potential, as evidenced by our initiatives with Actimab-M and Actimab-MDS. Dr. Ludwig is well suited to drive future efforts to utilize the power of the AWE technology for both the Company and collaborators. It is exciting to continue to strengthen the leadership team at Actinium. With each successive hire our capabilities become amplified which enables us to better drive toward the expected clinical milestones related to the Iomab-B, Actimab-A, Actimab-M and Actimab-MDS programs as well as our AWE platform, and to unlock the value inherent in Actinium.”

About Our Actinium Warhead Enabling Technology Platform
The Actinium Warhead Enabling (AWE) Technology Platform enables a highly potent and selective form of targeted therapy that combines the powerful alpha-emitting radioisotope actinium-225 with targeting agents which are designed to seek out cancer cells in the body that express particular markers. Actinium-225 emits significant alpha radiation making it a potent treatment modality against targeted cancer cells while limiting damage to healthy tissues as its radiation travels extremely short distances in the body. When labeled to targeting agents, actinium-225 can be delivered directly to cancer cells where the high linear energy transfer resulting from the emission of alpha particles results in irreparable DNA double stranded breaks and ultimately cancer cell death.  Despite this superior cell killing power, actinium-225 when delivered in a targeted manner is sparing of the surrounding environment in the body due to the short path length of its alpha-particle radiation and can result in a superior safety profile. Actinium Pharmaceuticals owns or has licensed the rights to several issued and pending patents that pertain to its AWE Technology Platform including technology to manufacture actinium-225 in a cyclotron. In addition, the Company has developed considerable know-how, expertise and validated processes related to production of Antibody Radio-Conjugates or ARC’s, management of the supply chain, and dealing with various regulatory bodies. The AWE Technology Platform can be utilized to potentially improve the cell-killing power of targeting agents such as antibodies, peptides, Fab fragments, nanobodies etc. via labeling with actinium-225. In addition to increased efficacy, these actinium-225 enhanced targeting agents can offer optimized dosing or administration and in the case of approved targeting agents provide an opportunity to extend intellectual property protection by the creation of biobetters or improved versions of the approved agent. The Company’s Actinium Warhead Enabling (AWE) Program can be accessed by biopharmaceutical companies that are interested in creating biobetters through the utilization of the AWE Platform Technology. To learn more about the AWE Technology Platform or the AWE Program please contact Keisha Thomas, Ph.D., Corporate Development at kthomas@actiniumpharma.com.

About Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing targeted therapies for potentially superior myeloablation and conditioning of the bone marrow prior to a bone marrow transplant and for the targeting and killing of cancer cells. Our targeted therapies have demonstrated the potential to result in significantly improved access to bone marrow transplant with better outcomes, namely increased marrow engraftment and survival. Our targeted therapies are ARC’s or Antibody Radio-Conjugates that combine the targeting ability of monoclonal antibodies with the cell killing ability of radioisotopes. Three of our four ARC drug candidates are based on our AWE or Actinium Warhead Enabling Technology Platform that utilizes the isotope Actinium-225 (Ac225) that emits alpha particles. We are currently conducting clinical trials for our four product candidates; Iomab-B, Actimab-A Actimab-M and Actimab-MDS, as well as performing research on other potential drug candidates utilizing our proprietary AWE Technology Platform. Our most advanced product candidate, Iomab-B, an ARC developed by the Fred Hutchinson Cancer Research Center, is comprised of an anti-CD45 monoclonal antibody labeled with iodine-131. We are currently conducting a pivotal Phase 3 trial of Iomab-B for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. A bone marrow transplant is a potentially curative treatment for patients with AML and other blood cancers including leukemias, lymphomas and multiple myeloma as well as certain blood disorders. Iomab-B has been tested in several of these other cancers with over five hundred patients treated in several Phase 1 and 2 trials with promising results. Upon successful completion of our Phase 3 clinical trial for Iomab-B we intend to submit this candidate for marketing approval in the U.S. and European Union where it has been designated as an Orphan Drug. We are also developing a potentially best in class CD33 program using an ARC comprised of the anti-CD33 monoclonal antibody lintuzumab labeled with the alpha-particle emitter actinium-225. Our most advanced CD33 program candidate, Actimab-A, is currently in a Phase 2 clinical trial for patients advanced over the age of 60 who are newly diagnosed with AML and ineligible for standard induction chemotherapy. Actimab-A also has Orphan Drug designation in the US and EU. Actimab-M, our second CD33 targeting ARC, is being studied in a Phase 1 trial for patients with refractory multiple myeloma. Actinium is also planning a Phase 2 trial for Actimab-MDS, our third CD33 program candidate, as a conditioning regimen prior to a bone marrow transplant for patients with MDS that have a p53 genetic mutation. Our AWE or Actinium Warhead Enabling Technology Platform, originally developed in conjunction with Memorial Sloan Kettering Cancer Center, is focused on leveraging Actinium’s know how and intellectual property to create additional ARC drug candidates by labeling Ac225 to targeting moieties that we will either progress in clinical trials ourselves or out-license. 

More information is available at www.actiniumpharma.com

Monday, February 5, 2018

Emerald Health Therapeutics Achieves Tier 1 Listing on TSX Venture Exchange


Source:  Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) has announced that in accordance with TSX Venture Exchange Policy 2.5, the Company has met the requirements for and been upgraded to a Tier 1 company.

The TSX Venture Exchange classifies issuers as “Tier 1” or “Tier 2” based on standards regarding historical financial performance, stage of development, and financial resources. Tier 1 is the highest tier of the TSX-V and is reserved for more advanced issuers with greater financial resources. Tier 1 issuers benefit from less stringent filing requirements. 

“Our team has been working diligently to meet our stated cannabis production scaling objectives, progress our product innovation strategy, and advance a differentiating marketing plan. In conjunction with these efforts our valuation and financial resources have been increasing and we are pleased that our accomplishments have allowed us to attain a higher listing status on the TSX Venture Exchange,” said Chris Wagner, CEO of Emerald Health Therapeutics. 

About Emerald Health Therapeutics
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.

Emerald Health Therapeutics and Namaste Technologies Announce Letter of Intent for International Partnership and Supply Agreement


Source:  Emerald Health Therapeutics, Inc.

Emerald Health Therapeutics Inc. (“Emerald”) (TSXV:EMH) (OTCQX:EMHTF) and Namaste Technologies Inc. (“Namaste”) (CSE:N) (FRANKFURT:M5BQ) (OTCMKTS:NXTTF) have signed a Letter of Intent (“LOI”) whereby Namaste and Emerald propose to enter into a definitive agreement (the “Proposed Agreement”) to collaborate on strategic business opportunities worldwide and develop a fully-integrated e-commerce platform (the “Platform”) to serve as a retail channel for Emerald’s patients. Under the terms of the Proposed Agreement, the companies would leverage Namaste’s existing consumer databases, site traffic and e-commerce technology for marketing purposes along with Emerald’s pharmaceutical and biotech expertise to develop medical cannabis downstream products tailored to specific markets and patients.

The e-commerce platform will be developed using Namaste’s technology, including machine learning algorithms and advanced on-site optimization techniques, and is planned to be available on desktop and mobile devices. Through the Platform Namaste would make available its full product catalog of over 1000+ cannabis delivery devices to Emerald for sale to its patients. This e-commerce platform is planned to connect to Namaste’s inventory management system and be compliant with Canada’s Access to Cannabis for Medical Purposes (“ACMPR”) regulations.

Under the LOI, Emerald will enter into a medical cannabis Supply Agreement with Namaste’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”), whereby Emerald would supply proprietary strains of medical cannabis to Cannmart, a late-stage ACMPR applicant for a medical cannabis “sales-only” license. Emerald is an ACMPR licensed producer of medical cannabis that cultivates proprietary cannabis strains using proven growing methods backed by cutting-edge research. Cannmart, with its “sales-only” platform, intends to impact the medical cannabis online-retail industry in Canada as it focuses on bringing a larger variety of medical cannabis products from many licensed producers, both domestically and abroad, in an easy-to-use platform for patients. 

“Emerald’s goal is to offer a broad selection of cannabis products to adult consumers through various legal channels, including digital and physical stores,” said Avtar Dhillon, Executive Chairman of Emerald. “We believe that combining Namaste’s online marketing tools and expertise, large and growing customer base, and array of cannabis delivery products with our proprietary cannabis strains and product development expertise can build significant incremental sales in legal markets in Canada and internationally.”

Sean Dollinger, President and CEO of Namaste comments: “We see great value in working with Emerald to develop a vertically integrated platform, starting with driving site traffic through to acquiring patients and offering them high quality medical cannabis products. Our goal with Cannmart is to offer the largest selection of medical cannabis products to our patient base in Canada. We look forward to exploring similar opportunities with Emerald internationally. Thanks to Emerald’s management team and Executive Chairman for the amazing communication and collaboration in developing this concept and we look forward to bringing this vision to reality.” 

Subject to obtaining necessary stock exchange approvals, on signing of the Proposed Agreement and Supply Agreement Namaste would receive 500,000 warrants of Emerald Health Therapeutics Inc. and Emerald Health Therapeutics Inc. would receive 500,000 warrants of Namaste. All such warrants would be priced in accordance with applicable stock exchange policies.

About Emerald Health Therapeutics
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada's Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald's team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

Emerald Health Therapeutics and DMG Blockchain Solutions Establish LOI to Create Cannabis Supply Chain Management System and E-Commerce Platform


Source:  Emerald Health Therapeutics, Inc.

Joint venture Cannachain Technologies would leverage blockchain technology designed to achieve unprecedented seed-to-sale provenance, safety and efficiency for the legal cannabis industry

Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) and Emerald Health Sciences, Inc. (together, “Emerald”) and DMG Blockchain Solutions Inc. (“DMG”) have completed a letter of intent to form a joint venture, to be named CannaChain Technologies (“Cannachain”), to develop a foundational blockchain-based supply chain management system and e-commerce marketplace for the legal cannabis industry. 

From Licensed Producers, through testing, distribution and other steps, to the consumer, the cannabis supply chain includes many touchpoints. CannaChain’s supply chain management system platform will aim to provide total transparency and assurances for end consumers about where a cannabis product came from and regarding an array of related attributes. The platform will also assist in ensuring adherence to Health Canada reporting requirements. By logging each step along the supply chain on the blockchain - a decentralized, timestamped, and unhackable digital ledger - this ground-breaking platform is expected to provide an irrefutable record outlining the journey the product has made, from beginning to end. 

“There are notable new applications of blockchain technology to validate and assure the source, quality and integrity of products such as diamonds, wine, and art, along with coffee and other food products,” said Avtar Dhillon, MD, Executive Chairman of Emerald Health Therapeutics. “Cannabis is also a prime industry in which to apply blockchain supply management based on the broad spectrum of plant and growing attributes, as well as product innovation potential; the growing trend of medical and in some cases recreational legalization, with the need for licensing as well as high security and confidence; and the possibility to start off such an initiative with relatively small groups of pertinent stakeholders. Canada’s established experience with medical cannabis regulations also lends it to new innovation in areas such as supply chain operations.”

In this joint venture, Emerald would provide its expertise and relationships as one of the earliest Canadian Licensed Producers under Access to Cannabis for Medical Purposes Regulations. DMG Blockchain Solutions, a blockchain supply chain management solution developer and leading crypto mining hosting provider, would build and deploy a blockchain supply chain management solution designed to meet the challenges and opportunities of the cannabis industry. The Cannachain solution is intended to provide extensive plant, growing, third-party testing, and handling data, and offer enhanced trust of origin, quality, and safety based on blockchain’s ability to maintain immutable records as cannabis products flow from seed-to-sale through the supply chain. The solution would serve relevant stakeholders including producers, distributors, shippers, government agencies, and consumers. 

Adrian Glover, DMG’s Director of Software Engineering, commented, “Supply chain management for cannabis is an ideal use case for blockchain’s tamper-proof ledger technology. We are excited to partner with Emerald and, through the formation of CannaChain Technologies, to provide such an integral solution for the Canadian medicinal market.”

The parties also intend that Cannachain would develop an e-commerce marketplace based on the blockchain-based supply chain management system to facilitate the sale of a broad product selection backed by unprecedented supporting data and trust. 

These solutions would be designed to also provide significant advantages with respect to administration of transactions, payments and reporting. 

CannaChain’s supply chain management platform will leverage an existing open source blockchain platform, enabling cross-industry collaboration capable of supporting global business transactions with major technology, financial, and supply chain companies. These tools will enable smart contract functionality, imperative to the automation of trust.  Regulatory reporting requirements would be automated by the platform, making for a seamless, supply chain management solution for Licensed Producers.

The parties intend to commence negotiation of definitive documentation relating to CannaChain and the development of the supply chain management solution. Key terms such as ownership of the joint venture, fees and commissions have not been finalized at this stage. Development of the supply chain management solution will not commence until after final terms have been settled and definitive documentation has been executed.

About DMG Blockchain Solutions
DMG Blockchain Solutions Inc. is a full service blockchain and cryptocurrency company that manages, operates and develops end-to-end solutions to monetize the blockchain ecosystem. DMG intends to be the global leader in crypto mining hosting, Mining as a Service (MaaS), crypto mining, forensics and diversified blockchain platform development.

About Emerald Health Therapeutics
Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. ("Botanicals"), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Through Botanicals, Emerald is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 500,000 s.f. greenhouse on 32 acres in Metro Vancouver, with expansion potential to 1 million s.f. to serve the anticipated legal Canadian adult-use cannabis market starting in 2018. Emerald also owns 50% of Pure Sunfarms Inc., a partnership with Village Farms International Inc. that is converting an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald is part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits by interacting with the human body’s endocannabinoid system.